Biocon Ltd
Exciting Insights from Biocon Ltd & Equillium's Itolizumab Study!
š Key Highlights:
- Biocon Ltd & Equillium Inc. reveal positive Phase 2 study results for itolizumab.
- Achieved a clinical remission rate of 23.3% at 12 weeks, surpassing adalimumab (20%) and placebo (10%).
- Key secondary endpoint: endoscopic remission for itolizumab at 16.7%, equal to adalimumab; placebo at 6.7%.
- Study design: Double-blind involving 90 patients on itolizumab, placebo, or adalimumab every two weeks for 12 weeks.
- Participants had a median age of 39, with 23% classified as severe in the itolizumab group.
- Well tolerated: No safety signals reported!
- Study co-sponsored by Equillium & Biocon, conducted across multiple clinical sites in India.
- Look out for additional data in 2025 at a scientific conference!